Steven I. Sherman,Lori J. Wirth,Jean-Pierre Droz,Michael Hofmann,Lars Bastholt,Renato Martins,Lisa Licitra,Michael Eschenberg,Yu-Nien Sun,Todd Juan,Daniel E. Stepan,Martin Schlumberger
The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT.